FSD PHARMA B (0K9.F)
| Previous Close | 0.2795 |
| Open | 0.2700 |
| Bid | 0.2670 x N/A |
| Ask | 0.3000 x N/A |
| Day's Range | 0.2700 - 0.2700 |
| 52 Week Range | 0.2700 - 1.2450 |
| Volume | |
| Avg. Volume | 155 |
| Market Cap | 11.869M |
| Beta (5Y Monthly) | 0.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
TORONTO, ON / ACCESSWIRE / May 16, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu"), its new packaging and logo of unbuzzd™ expected to ...
- ACCESSWIRE
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
TORONTO, ON / ACCESSWIRE / May 7, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments ...
- ACCESSWIRE
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
TORONTO, ON / ACCESSWIRE / April 30, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" of the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment ...
